Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Net loss before noncontrolling interests	$ (29,932)	$ (13,668)	$ (78,666)	$ (36,447)
Net loss attributable to noncontrolling interest	3,806	1,441	10,143	3,318
Net loss - as reported, attributable to PAVmed Inc.	(26,126)	(12,227)	(68,523)	(33,129)
Series B Convertible Preferred Stock dividends – earned	(71)	(67)	(209)	(216)
Net loss attributable to PAVmed Inc. common stockholders	$ (26,197)	$ (12,294)	$ (68,732)	$ (33,345)
Weighted average common shares outstanding, basic and diluted	89,758,927	83,307,170	87,724,124	79,873,583
Net loss - as reported, attributable to PAVmed Inc.	$ (0.29)	$ (0.15)	$ (0.78)	$ (0.41)
Net loss attributable to PAVmed Inc. common stockholders	$ (0.29)	$ (0.15)	$ (0.78)	$ (0.42)